One Step Ahead by Amundi ETFOne Step Ahead by Amundi ETF

Giving genes the silent treatment, with Dicerna Pharmaceuticals

View descriptionShare

One Step Ahead by Amundi ETF

Technological innovation and the need to live more sustainably are profoundly reshaping how we travel, work and play. In this podcast, business leader 
6 clip(s)
Loading playlist

***As of 28 December 2021, Novo Nordisk completed its acquisition of Dicerna Pharmaceuticals. This episode was recorded prior to the acquisition on 26 August 2021.***

In this episode of One Step Ahead, Douglas Fambrough, Ph.D., President and CEO at Dicerna Pharmaceuticals, talks us through “RNA interference,” an innovative technique that can target and silence certain disease-causing genes. From kidney-related disease to neurological disorders – and potentially even alcohol use disorder – he asserts that gene-based medicines have the potential to be a safe and effective approach to treating disease. According to Dr. Fambrough, we’re at the early stages of a “big bang” for gene-based medicine, and RNAi is just one of many disruptive technologies set to change the future of healthcare.

This episode was presented by Libby Potter.

  • Facebook
  • Twitter
  • WhatsApp
  • Email
  • Download

In 1 playlist(s)

  1. One Step Ahead by Amundi ETF

    6 clip(s)

One Step Ahead by Amundi ETF

Technological innovation and the need to live more sustainably are profoundly reshaping how we trave 
Social links
Follow podcast
Recent clips
Browse 6 clip(s)